# Retatrutide Half-Life and Pharmacokinetics: The Phase 1b PK Data

> Retatrutide half life is approximately 6 days, supporting once-weekly subcutaneous dosing. Full Phase 1b pharmacokinetic data — Cmax, Tmax, AUC, albumin-binding mechanism — cited from the published record.

Why a 6-day half-life means once-weekly dosing, how the albumin-binding chemistry produces it, and what the Phase 1b PK data actually show.

## The short version

Retatrutide half life — the time it takes for half the compound to clear from the blood — is approximately 6 days. That number matters because it is what makes once-weekly injection practical: a drug with a 2-hour half-life would need daily or twice-daily dosing; one with a 6-day half-life holds a useful blood level for the full week between injections.

The chemistry behind it: retatrutide's 39-amino-acid peptide chain has a C20 fatty-diacid molecular tail attached (acylation). That tail binds reversibly to albumin — the main protein in blood plasma — turning the peptide into an albumin-carried drug that circulates slowly rather than clearing quickly through the kidneys. The same albumin-binding design is used in other long-acting peptide drugs in this class.

This page covers the pharmacokinetic (PK) data from Phase 1b and explains what the key numbers mean. For trial efficacy outcomes, see [retatrutide results](/results).

## Retatrutide half-life: the Phase 1b data

The first-in-human Phase 1b trial (72 adults with type 2 diabetes, multiple-ascending-dose design, 12 weeks, subcutaneous once weekly) established the key pharmacokinetic parameters [4]:

- **Half-life: ~6 days.** Supports once-weekly administration with stable trough concentrations.
- **Route: subcutaneous injection, once weekly.** No other route has been studied in humans.
- **Placebo-adjusted weight at highest dose group: -8.96 kg** (90% CI -11.16 to -6.75 kg) over 12 weeks.
- **Fasting glucose at 3 mg: -2.8 mmol/L** versus placebo.
- **TEAEs in 63%** across all dose groups, predominantly GI (nausea, vomiting), considered acceptable at all doses.

The 6-day half-life figure is consistent with the albumin-binding mechanism. For comparison, endogenous GLP-1 has a half-life of approximately 2 minutes; unmodified GIP approximately 5–7 minutes. The acylation transforms retatrutide from a rapidly-cleared peptide into a slowly-circulating depot compound.

## Albumin binding: the molecular mechanism of extended half-life

Retatrutide's molecular formula is C221H342N46O68 (free acid), molecular weight 4731.33 Da. The C20 fatty-diacid acylation — a 20-carbon fatty acid chain attached chemically to the peptide backbone — is the key pharmacokinetic engineering element.

Albumin (serum albumin, the most abundant blood plasma protein) has multiple hydrophobic (water-repelling) binding sites. The fatty-acid tail on retatrutide binds to these sites, creating a reversible non-covalent complex. In this bound form, the peptide cannot be filtered by the kidneys or degraded by circulating proteases (enzymes that break down proteins). It is released slowly from albumin as free peptide, maintaining low but active plasma concentrations between weekly doses.

Cryo-EM structural studies confirm retatrutide engages GLP-1R, GIPR, and GCGR with defined receptor-binding geometry [3]. The acylation tail is not part of the receptor-binding interface — it extends outward to mediate albumin binding while the peptide's N-terminus and central region engage the receptor extracellular domains.

## Dose escalation and PK implications

Phase 1b dose groups tested: 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg subcutaneous once weekly. The ascending groups represent within-participant titration — participants started at the lower dose and stepped up on a defined schedule [4].

Slowing the escalation rate reduces peak plasma concentration spikes that drive GI adverse events. Reviews confirm this is the primary toleration mechanism across the GLP-1 drug class [7]. A 2025 systematic review of GI adverse effects in anti-obesity medications specifically recommended tailored titration and standardized adverse-event reporting [12].

The steady-state plasma level at a given dose (after 4–5 half-lives of weekly dosing) is what drives sustained receptor occupancy. With a ~6-day half-life and once-weekly dosing, plasma concentrations build gradually toward a stable plateau — which is why the Phase 2 obesity trial's weight loss curve continued descending through 48 weeks rather than flattening early [1].

## What the PK data does not tell you

Phase 1b PK data describe pharmacokinetics in a monitored clinical trial with GMP-manufactured, verified-identity compound. These parameters do not apply to gray-market research-labeled material of unknown purity, unknown amino-acid sequence, and unknown actual peptide content.

Bioavailability of subcutaneous peptides depends on injection technique, injection site, and formulation quality — all controlled in a clinical trial, none controlled in a gray-market context. A lyophilized powder that contains the wrong peptide, a truncated sequence, or a degraded product will not behave like the trial compound. The ~6-day half-life is a property of pharmaceutical-grade retatrutide, not of any research-labeled material.

---

A no-vendor reading of the retatrutide trial record — Phase 2 numbers read straight from the source, Phase 3 gaps named as gaps, and nothing here scripted, dispensed, or sold.